The following video is from Tuesday's MarketFoolery, in which host Chris Hill and Motley Fool analysts Tim Hanson and Matt Koppenheffer take a Foolish stroll through the biggest business and investing stories of the day.
In what will be the third-largest pharmaceutical settlement in U.S. history, Johnson & Johnson (NYSE:JNJ) has agreed to pay more than $2.2 billion in criminal and civil fines to settle accusations that it improperly promoted the antipsychotic drug Risperdal to older adults, children, and people with developmental disabilities. JNJ CEO Alex Gorsky served both as the vice president for sales and marketing and later the president of the company's pharmaceutical unit during the period in question, between 1999 and 2005. Should Gorsky be ousted for his role in the scandal? In this segment, our analysts discuss Gorsky, Johnson & Johnson, and the severity of the accusations.
Chris Hill owns shares of Johnson & Johnson. Matt Koppenheffer and Tim Hanson have no position in any stocks mentioned. The Motley Fool recommends and owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.